Clinical trials recruiting for Lung Adenocarcinoma

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer
  NCT05558904 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
  NCT03199651 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
  NCT06255197 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
  NCT06843629 · Phase: Not specified · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
  NCT05838053 · Phase: Not specified · Ages: 20 Years to 79 Years · Sex: All (male and female) · 1 location
• Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma
  NCT04339218 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• DBC-664 in Adult Patients With Solid Tumors
  NCT07705035 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic
  NCT06056115 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Engagement of Veterans With Lung Cancer
  NCT07219251 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma
  NCT07636252 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
  NCT04119024 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
  NCT05537922 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic-predominant Growth Lung Adenocarcinoma
  NCT07479095 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Lymph Node Pathologic Grading Strategy
  NCT06745830 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma
  NCT05528458 · Phase: Phase 2 · Ages: 30 Years to 75 Years · Sex: All (male and female) · 1 location
• Partial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer
  NCT07423169 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Pathogenic Variants in Genes Associated With Lung Adenocarcinoma
  NCT06181812 · Phase: Not specified · Ages: 16 Years to 85 Years · Sex: All (male and female) · 1 location
• Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
  NCT05266846 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients
  NCT07012759 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
  NCT05517811 · Phase: Not specified · Ages: 18 Years to 99 Years · Sex: All (male and female) · 4 locations
• SL-28 for Advanced Solid Tumours
  NCT07341737 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
  NCT04937283 · Phase: Not applicable (e.g. observational or device study) · Ages: 20 Years to 79 Years · Sex: All (male and female) · 14 locations
• Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)
  NCT05717803 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Segmentectomy for Solid-dominant Lung Cancer
  NCT06634966 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)
  NCT06031246 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Shared Decision Making in Patients With Lung Cancer
  NCT05191485 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)
  NCT06031181 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
  NCT05198830 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 34 locations
• Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma
  NCT07235280 · Phase: Early Phase 1 · Ages: 22 Years and older · Sex: All (male and female) · 1 location
• Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib
  NCT07633626 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• WSI Based DL for Diagnosing the IASLC Grading System of Lung Adenocarcinoma
  NCT05925764 · Phase: Not specified · Ages: 18 Years to 85 Years · Sex: All (male and female) · 3 locations

Related conditions

Trials recruiting for Lung Adenocarcinoma often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Lung Adenocarcinoma trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.